Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · Co-Chief Executive Officer · 10% owner | June 12, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 14,504 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 14,504 · Balance 14,504 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Summit Therapeutics Inc.
Report date June 12, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 573,883,879 |
Reported balance
After 2026-06-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 3,810,000 · Balance 573,883,879 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | 25,824,474 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,824,474 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectImmediate family member | 76,680 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,680 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee | 10,199,776 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 10,199,776 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 31,000 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 31,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 12, 2026 18:35 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 3,810,000 | $13.12 | $49,987,200.00 |
DisclosureSEC source: 0001507650-26-000007 · wk-form4_1781289308.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 573,883,879 F1 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 01:21 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 14,504 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020722 · rdgdoc.xml · derivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,504 Underlying: Common Stock · 14,504 shares Expires 2036-06-11 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 01:21 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020722 · rdgdoc.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 100,000 | $14.60 | $1,460,000.00 |
DisclosureSEC source: 0001507650-26-000005 · wk-form4_1780609499.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee Disclosed balance after: 25,824,474 F1 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:52 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 11,232 | $8.76 Strike: $17.52 | $98,392.32 |
DisclosureSEC source: 0001507650-26-000003 · wk-form4_1767747171.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 11,232 Underlying: Common Stock · 11,232 shares Expires 2036-01-02 F2 · price: The option was issued to the reporting person's spouse pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $98,400. F1 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person's spouse remaining as a non-salaried director on each such vesting date. F3 · balance_after: The reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 20:06 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock | 13,980,789 | $18.74 | $261,999,985.86 |
DisclosureSEC source: 0001507650-25-000003 · wk-form4_1761249988.xml · nonDerivative · entry 3 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 570,073,879 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 20:06 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 26,680 | $18.74 | $499,983.20 |
DisclosureSEC source: 0001507650-25-000003 · wk-form4_1761249988.xml · nonDerivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Immediate family member Disclosed balance after: 76,680 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 20:06 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock | 266,808 | $18.74 | $4,999,981.92 |
DisclosureSEC source: 0001507650-25-000003 · wk-form4_1761249988.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee Disclosed balance after: 25,724,474 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 23:36 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 5,000 | $18.07 | $90,350.00 |
DisclosureSEC source: 0001599298-25-000143 · wk-form4_1757633787.xml · nonDerivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 556,093,090 F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 23:36 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 333,394 | $17.68 | $5,894,405.92 |
DisclosureSEC source: 0001599298-25-000143 · wk-form4_1757633787.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 556,088,090 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.49 to $17.89 per share, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 01:23 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 24,134 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001437749-25-027396 · rdgdoc.xml · derivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,134 Underlying: Common Stock · 24,134 shares Expires 2035-08-15 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2025. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 01:23 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001437749-25-027396 · rdgdoc.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-08-15 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 21:01 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionStock Option (right to buy) · Derivative | 74,545 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001599298-25-000107 · wk-form4_1748898068.xml · derivative · entry 6 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 74,545 shares Expires 2034-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 30, 2025, the Reporting Person's spouse exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of $2.64 per share. The Reporting Person's spouse did not sell the underlying shares. F3 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option vested in four equal quarterly installments on March 31, June 30, September 30 and December 31, 2024. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 21:01 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionCommon Stock | 74,545 | $2.64 | $196,798.80 |
DisclosureSEC source: 0001599298-25-000107 · wk-form4_1748898068.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 555,754,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 30, 2025, the Reporting Person's spouse exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of $2.64 per share. The Reporting Person's spouse did not sell the underlying shares. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:03 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 9,590,558 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001599298-25-000091 · wk-form4_1746137015.xml · derivative · entry 3 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,590,558 Underlying: Common Stock · 9,590,558 shares Expires 2033-10-13 F2 · price: Not applicable. F1 · derivative.exercise_date: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:03 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 400,000 | Not disclosed Strike: $1.29 | Not disclosed |
DisclosureSEC source: 0001599298-25-000091 · wk-form4_1746137015.xml · derivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-09-09 F2 · price: Not applicable. F1 · derivative.exercise_date: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:03 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 1,040,000 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0001599298-25-000091 · wk-form4_1746137015.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,040,000 Underlying: Common Stock · 1,040,000 shares Expires 2032-06-28 F2 · price: Not applicable. F1 · derivative.exercise_date: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025. Read SEC document |
| April 08, 2025 Filed Apr 9, 2025 21:19 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherWarrant (right to buy) · Derivative | 3,985,055 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001599298-25-000060 · wk-form4_1744233562.xml · derivative · entry 6 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 3,985,055 shares Expires 2029-12-24 F1 · kind: On April 8, 2025, the Reporting Person's spouse exercised warrants to purchase an aggregate of 3,985,055 shares of the Issuer's common stock at an exercise price of $1.58 per share F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 08, 2025 Filed Apr 9, 2025 21:19 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherCommon Stock | 3,985,055 | $1.58 | $6,296,386.90 |
DisclosureSEC source: 0001599298-25-000060 · wk-form4_1744233562.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 555,680,151 F1 · kind: On April 8, 2025, the Reporting Person's spouse exercised warrants to purchase an aggregate of 3,985,055 shares of the Issuer's common stock at an exercise price of $1.58 per share F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 03, 2025 Filed Feb 11, 2025 23:20 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 30,121 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001437749-25-003449 · rdgdoc.xml · derivative · entry 7 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,121 shares Expires 2029-07-03 Read SEC document |
| February 03, 2025 Filed Feb 11, 2025 23:20 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 30,121 | $11.00 | $331,331.00 |
DisclosureSEC source: 0001437749-25-003449 · rdgdoc.xml · nonDerivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 725,395 Read SEC document |
| January 24, 2025 Filed Feb 11, 2025 23:20 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 30,121 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001437749-25-003449 · rdgdoc.xml · derivative · entry 6 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,121 shares Expires 2029-07-03 Read SEC document |
| January 24, 2025 Filed Feb 11, 2025 23:20 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 30,121 | $11.00 | $331,331.00 |
DisclosureSEC source: 0001437749-25-003449 · rdgdoc.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,274 Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:39 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 10,724 | $9.18 Strike: $18.35 | $98,446.32 |
DisclosureSEC source: 0001599298-25-000029 · wk-form4_1736210375.xml · derivative · entry 6 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 10,724 Underlying: Common Stock · 10,724 shares Expires 2035-01-02 F3 · derivative.exercise_date: The option was granted on January 2, 2025 to the Reporting Person's spouse. The shares underlying the option shall vest in four quarterly installments, subject to continued service on each vesting date. F1 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 03, 2024 Filed Oct 3, 2024 20:54 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherWarrant (right to buy) · Derivative | 315,681 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001599298-24-000146 · wk-form4_1727988861.xml · derivative · entry 5 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee Disclosed balance after: 0 Underlying: Common Stock · 315,681 shares Expires 2029-12-24 F1 · kind: On October 3, 2024, the Shaun Zanganeh Irrevocable Trust exercised a warrant to purchase 315,681 shares of the Issuer's common stock at an exercise price of $1.58 per share. Read SEC document |
| October 03, 2024 Filed Oct 3, 2024 20:54 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherCommon Stock | 315,681 | $1.58 | $498,775.98 |
DisclosureSEC source: 0001599298-24-000146 · wk-form4_1727988861.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee Disclosed balance after: 10,199,776 F1 · kind: On October 3, 2024, the Shaun Zanganeh Irrevocable Trust exercised a warrant to purchase 315,681 shares of the Issuer's common stock at an exercise price of $1.58 per share. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 23:29 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock | 44,052 | $22.70 | $999,980.40 |
DisclosureSEC source: 0001599298-24-000141 · wk-form4_1726270177.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee Disclosed balance after: 24,967,852 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee, at a purchase price of $22.70 per share. The transaction closed on September 13, 2024. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 23, 2024 Filed Aug 23, 2024 20:42 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantPerformance Stock Option (right to buy) · Derivative | 2,397,640 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001599298-24-000123 · wk-form4_1724445740.xml · derivative · entry 3 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,397,640 Underlying: Common Stock · 2,397,640 shares Expires 2033-10-13 F2 · price: Not applicable. F4 · derivative.exercise_date: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 9,590,558 shares underlying options which were granted on October 13, 2023 that remain subject to the satisfaction of performance conditions. Read SEC document |
| August 23, 2024 Filed Aug 23, 2024 20:42 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantPerformance Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $1.29 | Not disclosed |
DisclosureSEC source: 0001599298-24-000123 · wk-form4_1724445740.xml · derivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-09 F2 · price: Not applicable. F3 · derivative.exercise_date: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 400,000 shares underlying options which were granted on September 9, 2022 that remain subject to the satisfaction of performance conditions. Read SEC document |
| August 23, 2024 Filed Aug 23, 2024 20:42 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantPerformance Stock Option (right to buy) · Derivative | 260,000 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0001599298-24-000123 · wk-form4_1724445740.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2032-06-28 F2 · price: Not applicable. F1 · derivative.exercise_date: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 1,040,000 shares underlying options which were granted on June 28, 2022, that remain subject to the satisfaction of performance conditions. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 22:50 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001437749-24-026499 · rdgdoc.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-08-09 F1 · derivative.exercise_date: One-fourth of the shares subject to the option will vest on the date of the Issuer's next annual meeting of stockholders and the remaining shares will vest on a monthly basis over three years thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:20 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 30,121 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022360 · rdgdoc.xml · derivative · entry 6 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,121 Underlying: Common Stock · 30,121 shares Expires 2029-07-03 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:20 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 30,121 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022360 · rdgdoc.xml · derivative · entry 5 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,121 Underlying: Common Stock · 30,121 shares Expires 2029-07-03 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:20 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 60,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022360 · rdgdoc.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 665,153 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| June 06, 2024 Filed Jun 24, 2024 23:40 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 8,247 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001437749-24-021131 · rdgdoc.xml · derivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,247 Underlying: Common Stock · 8,247 shares Expires 2034-06-06 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2024. Read SEC document |
| June 06, 2024 Filed Jun 24, 2024 23:40 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001437749-24-021131 · rdgdoc.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 6, 2024. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 00:28 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 20,000 | $3.71 | $74,200.00 |
DisclosureSEC source: 0001599298-24-000047 · wk-form4_1711585700.xml · nonDerivative · entry 4 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Immediate family member Disclosed balance after: 50,000 F5 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.68 to $3.75 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 00:28 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 34,321 | $3.72 | $127,674.12 |
DisclosureSEC source: 0001599298-24-000047 · wk-form4_1711585700.xml · nonDerivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee Disclosed balance after: 24,923,800 F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.69 to $3.72 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 00:28 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 26,000 | $3.72 | $96,720.00 |
DisclosureSEC source: 0001599298-24-000047 · wk-form4_1711585700.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,814 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 00:28 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 30,000 | $3.75 | $112,500.00 |
DisclosureSEC source: 0001599298-24-000047 · wk-form4_1711585700.xml · nonDerivative · entry 3 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Immediate family member Disclosed balance after: 30,000 F4 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.78 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 22:11 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 5,000 | $2.07 | $10,350.00 |
DisclosureSEC source: 0001599298-23-000103 · wk-form4_1702505507.xml · nonDerivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494,814 F2 · shares: The Reporting Person purchased these shares in a single transaction on the open market. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 22:11 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherWarrant (right to buy) · Derivative | 315,681 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001599298-23-000103 · wk-form4_1702505507.xml · derivative · entry 5 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee Disclosed balance after: 0 Underlying: Common Stock · 315,681 shares Expires 2029-12-24 F1 · shares: The Reporting Person exercised certain warrants to purchase shares of common stock in accordance with the terms of such warrants. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 22:11 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherWarrant (right to buy) · Derivative | 489,814 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001599298-23-000103 · wk-form4_1702505507.xml · derivative · entry 4 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 489,814 shares Expires 2025-06-30 F1 · shares: The Reporting Person exercised certain warrants to purchase shares of common stock in accordance with the terms of such warrants. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 22:11 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherCommon Stock | 315,681 | $1.58 | $498,775.98 |
DisclosureSEC source: 0001599298-23-000103 · wk-form4_1702505507.xml · nonDerivative · entry 3 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee Disclosed balance after: 24,889,479 F1 · shares: The Reporting Person exercised certain warrants to purchase shares of common stock in accordance with the terms of such warrants. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 22:11 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherCommon Stock | 489,814 | $1.44 | $705,332.16 |
DisclosureSEC source: 0001599298-23-000103 · wk-form4_1702505507.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489,814 F1 · shares: The Reporting Person exercised certain warrants to purchase shares of common stock in accordance with the terms of such warrants. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:37 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 56,075 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001437749-23-032198 · rdgdoc.xml · derivative · entry 7 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,075 shares Expires 2032-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a quartetrly basis following the Company's 2022 Annual Stockholder Meeting. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:37 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001437749-23-032198 · rdgdoc.xml · derivative · entry 6 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a monthly basis following the Company's 2022 Annual Stockholder Meeting. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:37 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 56,075 | $2.14 | $120,000.50 |
DisclosureSEC source: 0001437749-23-032198 · rdgdoc.xml · nonDerivative · entry 2 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 604,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:37 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $2.14 | $42,800.00 |
DisclosureSEC source: 0001437749-23-032198 · rdgdoc.xml · nonDerivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 548,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 20:08 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 11,988,198 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001599298-23-000090 · wk-form4_1697486896.xml · derivative · entry 1 Zanganeh Mahkam · CIK 0001507650 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,988,198 Underlying: Common Stock · 11,988,198 shares Expires 2033-10-13 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on October 13, 2023. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on October 13, 2024. Note this does not include an additional 11,988,198 options which were granted on October 13, 2023 and are subject to the satisfaction of performance conditions based on market capitalization and revenue targets. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.